Tauopathies, including Alzheimer's disease (AD), are characterized by the pathological aggregation of tau proteins, culminating in progressive neurodegeneration and cognitive decline. Conventional therapeutic strategies remain limited by inadequate blood-brain barrier (BBB) penetration, insufficient specificity for tau pathology, and lack of real-time disease monitoring. While carbon-based nanomaterials have been extensively investigated for amyloid-β related applications, their potential for tau-directed theranostics remains at an early yet rapidly advancing state. Carbon-based nanomaterials–including carbon dots, fullerenes, graphene derivatives, and carbon nanotubes–exhibit exceptional physicochemical versatility, demonstrating potential to inhibit tau aggregation, scavenge reactive oxygen species (ROS), enable precision drug delivery, and facilitate ultrasensitive detection of tau biomarkers. Their inherent capacity for BBB penetration and dual diagnostic-therapeutic functionality positions them as transformative candidates for next-generation management of tauopathies. Despite this promise, most evidence remains preclinical, and major translational challenges persist. These include long-term biocompatibility and toxicological uncertainties, lack of standardized synthesis and functionalization protocols, production scalability, and the molecular heterogeneity of tau pathology across distinct tauopathies. This review provides a comprehensive assessment of carbon nanomaterials to date in the context of tau pathology, critically examining their theranostic potential and the barriers impeding clinical translation. By delineating current limitations and strategic priorities for future research, it underscores the urgent need for coordinated interdisciplinary efforts to convert these versatile nanoplatforms from conceptual promise to clinically actionable technologies for precision tau-targeted therapy.
TayLXOngSCTayLJ, et al.Economic burden of Alzheimer’s disease: a systematic review. Value Health Reg Issues2024; 40: 1–12.
2.
HarrisGAHirschfeldLR. Antisense oligonucleotides provide optimism to the therapeutic landscape for tauopathies. Neural Regen Res2025; 20: 803–804.
3.
LuoYYuHYeK. Distinct factors drive the progression of tau pathology in Alzheimer’s disease. Fundament ResEpub ahead of print 9 April 2025. DOI:10.1016/j.fmre.2025.04.001
4.
ChenYYuY. Tau and neuroinflammation in Alzheimer’s disease: interplay mechanisms and clinical translation. J Neuroinflammation2023; 20: 165.
5.
JieCVMLTreyerVSchibliR, et al.TauvidTM: the first FDA-approved pet tracer for imaging tau pathology in Alzheimer’s disease. Pharmaceuticals (Basel)2021; 14: 1–12.
6.
RobbinsM. Therapies for tau-associated neurodegenerative disorders: targeting molecules, synapses, and cells. Neural Regen Res2023; 18: 2633–2637.
7.
MoumnéLMarieACCrouvezierN. Oligonucleotide therapeutics: from discovery and development to patentability. Pharmaceutics2022; 14: 260.
8.
TartagliaMCIngelssonM. Molecular therapeutics in development to treat Alzheimer’s disease. Mol Diagn Ther2025; 29: 9–24.
9.
KevadiyaBDOttemannBMThomasMB, et al.Neurotheranostics as personalized medicines. Adv Drug Deliv Rev2019; 148: 252–289.
10.
ShabaniLAbbasiMAzarnewZ, et al.Neuro-nanotechnology: diagnostic and therapeutic nano-based strategies in applied neuroscience. Biomed Eng Online2023; 22: 1.
11.
VinodCJenaS. Nano-neurotheranostics: impact of nanoparticles on neural dysfunctions and strategies to reduce toxicity for improved efficacy. Front Pharmacol2021; 12: 612692.
12.
KhodarahmiGSabetiBChekinF. Carbon nanotubes/ordered mesoporous carbon/chitosan nanocomposite as a promising carrier for everolimus targeted delivery toward lung cancer cells. J Mater Sci Mater Med2025; 36: 46.
13.
MohajeriMBehnamBBarretoGE, et al.Carbon nanomaterials and amyloid-beta interactions: potentials for the detection and treatment of Alzheimer’s disease?Pharmacol Res2019; 143: 186–203.
14.
BaiMShaoXWangC, et al.Application of carbon-based nanomaterials in Alzheimer’s disease. Mater Horiz2025; 12: 673–693.
15.
ŞakBSousaHBAPriorJAV. Carbon nanomaterial-based electrochemical biosensors for Alzheimer’s disease biomarkers: progress, challenges, and future perspectives. Biosensors (Basel)2025; 15: 684.
16.
CaiJLiBZhangJ, et al.Advances in Alzheimer’s disease control approaches via carbon nanotubes. Nanomedicine2025; 20: 63–77.
17.
ZhouHYinXZhangG, et al.Advancing nanomaterial-based strategies for Alzheimer’s disease: a perspective. JACS Au2025; 5: 1519–1537.
18.
AbdullahSANajmLLadouceurL, et al.Functional nanomaterials for the diagnosis of Alzheimer’s disease: recent progress and future perspectives. Adv Funct Mater2023; 33: 2302673.
19.
WilsonDMCooksonMRVan Den BoschL, et al.Hallmarks of neurodegenerative diseases. Cell2023; 186: 693–714.
20.
GadhaveDGSugandhiVVJhaSK, et al.Neurodegenerative disorders: mechanisms of degeneration and therapeutic approaches with their clinical relevance. Ageing Res Rev2024; 99: 102357.
21.
KamathamPTShuklaRKhatriDK, et al.Pathogenesis, diagnostics, and therapeutics for Alzheimer’s disease: breaking the memory barrier. Ageing Res Rev2024; 101: 102481.
KamilaPKarKChowdhuryS, et al.Effect of neuroinflammation on the progression of Alzheimer’s disease and its significant ramifications for novel anti-inflammatory treatments. IBRO Neurosci Rep2025; 18: 771–782.
24.
ZhangXWangJZhangZ, et al.Tau in neurodegenerative diseases: molecular mechanisms, biomarkers, and therapeutic strategies. Transl Neurodegener2024; 13: 40.
25.
GuJLLiuF.Tau in Alzheimer’s disease: pathological alterations and an attractive therapeutic target. Curr Med Sci2020; 40: 1009–1021.
26.
BejaninASchonhautDRLa JoieR, et al.Tau pathology and neurodegeneration contribute to cognitive impairment in Alzheimer’s disease. Brain2017; 140: 3286–3300.
27.
WangYMandelkowE. Tau in physiology and pathology. Nat Rev Neurosci2016; 17: 22–35.
28.
BeeversJELaiMCCollinsE, et al.MAPT Genetic variation and neuronal maturity alter isoform expression affecting axonal transport in iPSC-derived dopamine neurons. Stem Cell Rep2017; 9: 587–599.
29.
CorsiABombieriCValentiMT, et al.Tau isoforms: gaining insight into MAPT alternative splicing. Int J Mol Sci2022; 23: 15383.
30.
Aranda-AbreuGERojas-DuránFHernández-AguilarME, et al.The role of tau in neuronal function and neurodegeneration. Neurol Int2025; 17: 75.
31.
HuJShaWYuanS, et al.Aggregation, transmission, and toxicity of the microtubule-associated protein tau: a complex comprehension. Int J Mol Sci2023; 24: 15023.
32.
GuoTNobleWHangerDP. Roles of tau protein in health and disease. Acta Neuropathol2017; 133: 665–704.
33.
TardivelMBégardSBoussetL, et al.Tunneling nanotube (TNT)-mediated neuron-to neuron transfer of pathological Tau protein assemblies. Acta Neuropathol Commun2016; 4: 117.
34.
KotarbaSKozłowskaMSciosM, et al.Potential mechanisms of tunneling nanotube formation and their role in pathology spread in Alzheimer’s disease and other proteinopathies. Int J Mol Sci2024; 25: 10797.
35.
ZhangHCaoYMaL, et al.Possible mechanisms of tau spread and toxicity in Alzheimer’s disease. Front Cell Dev Biol2021; 9: 707268.
36.
HooverBRReedMNSuJ, et al.Tau mislocalization to dendritic spines mediates synaptic dysfunction independently of neurodegeneration. Neuron2010; 68: 1067–1081.
37.
YinXZhaoCQiuY, et al.Dendritic/post-synaptic tau and early pathology of Alzheimer’s disease. Front Mol Neurosci2021; 14: 671779.
38.
AdamsSJde TureMAMcBrideM, et al.Three repeat isoforms of tau inhibit assembly of four repeat tau filaments. PLoS One2010; 5: e10810.
39.
AlquezarCAryaSKaoAW. Tau post-translational modifications: dynamic transformers of tau function, degradation, and aggregation. Front Neurol2021; 11: 595532.
40.
ParkSLeeJHJeonJH, et al.Degradation or aggregation: the ramifications of post-translational modifications on tau. BMB Rep2018; 51: 265–273.
41.
WangLSooramBKumarR, et al.Tau degradation in Alzheimer’s disease: mechanisms and therapeutic opportunities. Alzheimers Dement2025; 21: e70048.
42.
GuoYLiSZengL-H, et al.Tau-targeting therapy in Alzheimer’s disease: critical advances and future opportunities. Ageing Neur Dis2022; 2: 11.
43.
CummingsJLGonzalezMIPritchardMC, et al.The therapeutic landscape of tauopathies: challenges and prospects. Alzheimers Res Ther2023; 15: 168.
44.
ZhouFZhaoYSunY, et al.Molecular insights into tau pathology and its therapeutic strategies in Alzheimer’s disease. J Integr Neurosci2024; 23: 11.
45.
SinghSKhanSShahidM, et al.Targeting tau in Alzheimer’s and beyond: insights into pathology and therapeutic strategies. Ageing Res Rev2025; 104: 102639.
46.
MummeryCJBörjesson-HansonABlackburnDJ, et al.Tau-targeting antisense oligonucleotide MAPTRx in mild Alzheimer’s disease: a phase 1b, randomized, placebo-controlled trial. Nat Med2023; 29: 1437–1447.
47.
YukawaKYamamoto-McguireSCafaroL, et al.Antisense oligonucleotide-based targeting of Tau-tubulin kinase 1 prevents hippocampal accumulation of phosphorylated tau in PS19 tauopathy mice. Acta Neuropathol Commun2023; 11: 166.
48.
TanDCSYaoSIttnerA, et al.Generation of a new tau knockout (tau Δex1) line using CRISPR/Cas9 genome editing in mice. J Alzheimers Dis2018; 62: 571–578.
49.
YouYHershSWAslebaghR, et al.Alzheimer’s disease associated AKAP9 I2558M mutation alters posttranslational modification and interactome of tau and cellular functions in CRISPR-edited human neuronal cells. Aging Cell2022; 21: e13617.
50.
Iwata-EndoKSahashiKKawaiK, et al.Correcting tau isoform ratios with a long-acting antisense oligonucleotide alleviates 4R-tauopathy phenotypes. Mol Ther Nucleic Acids2025; 36: 102503.
51.
MuñizJAFacalCLUrrutiaL, et al.SMaRT modulation of tau isoforms rescues cognitive and motor impairments in a preclinical model of tauopathy. Front Bioeng Biotechnol2022; 10: 951384.
52.
EspíndolaSLDamianichAAlvarezRJ, et al.Modulation of tau isoforms imbalance precludes tau pathology and cognitive decline in a mouse model of tauopathy. Cell Rep2018; 23: 709–715.
53.
SilvaIMFDos Reis Rosa FrancoGGontijoVS, et al.Protein kinases as therapeutic targets for Alzheimer’s disease: a brief review. Explor Neuroprot Ther2024; 4: 411–441.
54.
GóralIWichurTSługockaE, et al.Connecting GSK-3β inhibitory activity with IKK-β or ROCK-1 inhibition to target tau aggregation and neuroinflammation in Alzheimer’s disease—discovery, in vitro and in cellulo activity of thiazole-based inhibitors. Molecules2024; 29: 2616.
55.
GongEJParkHRKimME, et al.Morin attenuates tau hyperphosphorylation by inhibiting GSK3β. Neurobiol Dis2011; 44: 223–230.
56.
SaitoTObaTShimizuS, et al.Cdk5 increases MARK4 activity and augments pathological tau accumulation and toxicity through tau phosphorylation at Ser262. Hum Mol Genet2019; 28: 3062–3071.
57.
MalhisMKaniyappanSAillaudI, et al.Potent tau aggregation inhibitor D-peptides selected against tau-repeat 2 using mirror image phage display. ChemBioChem2021; 22: 3049–3059.
58.
PaulAViswanathanGKKHuberA, et al.Inhibition of tau amyloid formation and disruption of its preformed fibrils by Naphthoquinone–Dopamine hybrid. FEBS J2021; 288: 4267–4290.
59.
SeidlerPMMurrayKABoyerDR, et al.Structure-based discovery of small molecules that disaggregate Alzheimer’s disease tissue derived tau fibrils in vitro. Nat Commun2022; 13: 5451.
60.
LiuXYeMMaL. The emerging role of autophagy and mitophagy in tauopathies: from pathogenesis to translational implications in Alzheimer’s disease. Front Aging Neurosci2022; 14: 1022821.
61.
GaikwadSPuangmalaiNSonawaneM, et al.Nasal tau immunotherapy clears intracellular tau pathology and improves cognitive functions in aged tauopathy mice. Sci Transl Med2024; 16: 754.
62.
XuLWuXZhaoS, et al.Harnessing nanochaperone-mediated autophagy for selective clearance of pathogenic tau protein in Alzheimer’s disease. Adv Mater2024; 36: e2313869.
63.
Fernandez-ValenzuelaJJSanchez-VaroRMuñoz-CastroC, et al.Enhancing microtubule stabilization rescues cognitive deficits and ameliorates pathological phenotype in an amyloidogenic Alzheimer’s disease model. Sci Rep2020; 10: 14776.
64.
PachimaYIZhouLYLeiP, et al.Microtubule-tau interaction as a therapeutic target for Alzheimer’s disease. J Mol Neurosci2016; 58: 145–152.
65.
LimJLLinCJHuangCC, et al.Curcumin-derived carbon quantum dots: dual actions in mitigating tau hyperphosphorylation and amyloid beta aggregation. Colloids Surf B Biointerfaces2024; 234: 113676.
66.
ZhangWSmithNZhouY, et al.Carbon dots as dual inhibitors of tau and amyloid-beta aggregation for the treatment of Alzheimer’s disease. Acta Biomater2024; 183: 341–355.
67.
ZhouYKandelNBartoliM, et al.Structure-activity relationship of carbon nitride dots in inhibiting tau aggregation. Carbon N Y2022; 193: 1–16.
68.
ZhangWKandelNZhouY, et al.Drug delivery of memantine with carbon dots for Alzheimer’s disease: blood–brain barrier penetration and inhibition of tau aggregation. J Colloid Interface Sci2022; 617: 20–31.
69.
WilsonDLAhlawatJNarayanM. The role of fullerenes in neurodegenerative disorders. J Nanotheranostics2024; 5: 1–12.
70.
NamYShinSJKumarV, et al.Dual modulation of amyloid beta and tau aggregation and dissociation in Alzheimer’s disease: a comprehensive review of the characteristics and therapeutic strategies. Transl Neurodegener2025; 14: 15.
71.
Martińez-HerreraMFigueroa-GerstenmaierSLópez-CamachoPY, et al.Multiadducts of C60 modulate amyloid-β fibrillation with dual acetylcholinesterase inhibition and antioxidant properties: in vitro and in silico studies. J Alzheimers Dis2022; 87: 741–759.
72.
XieLLuoYLinD, et al.The molecular mechanism of fullerene-inhibited aggregation of Alzheimer’s β-amyloid peptide fragment. Nanoscale2014; 6: 9752–9762.
73.
MalafaiaDAlbuquerqueHMTSilvaAMS. Amyloid-β and tau aggregation dual-inhibitors: a synthetic and structure-activity relationship focused review. Eur J Med Chem2021; 214: 113209.
74.
SoylemezSDolgunVÖzçubukçuS. Fullerene-based mimics of enhanced acetylcholine detection for the diagnosis of Alzheimer’s disease. Microchem J2023; 193: 109099.
75.
ShokouhiSTaylorWNewhouseP. Cholinergic degeneration in association with tau pathology and evidence of sex differences. Am J Geriatr Psychiatry2021; 29: S123–S124.
76.
ChenZRHuangJBYangSL, et al.Role of cholinergic signaling in Alzheimer’s disease. Molecules2022; 27: 1816.
77.
LuqueFJMuñoz-TorreroD. Acetylcholinesterase: a versatile template to coin potent modulators of multiple therapeutic targets. Acc Chem Res2024; 57: 450–467.
78.
AndalibSNikpourMHamidiM, et al.Evaluation and comparison of fullerene (C60) aqueous suspension administration effects with memantine HCL in rat model of Alzheimer’s disease considering behavioral patterns and spatial memory. J Microbiota2024; 1: e143061.
79.
IvkovicSKorugaD. Role of fullerenols derivative 3HFWC in the treatment of Alzheimer’s disease. Neural Regen Res2024; 19: 1641–1642.
80.
Sonuç KarabogaMNSezgintürkMK. Analysis of tau-441 protein in clinical samples using rGO/AuNP nanocomposite-supported disposable impedimetric neuro-biosensing platform: towards Alzheimer’s disease detection. Talanta2020; 219: 121257.
81.
HuangAZhangLLiW, et al.Controlled fluorescence quenching by antibody-conjugated graphene oxide to measure tau protein. R Soc Open Sci2018; 5: 171808.
82.
BodilyTARamanathanAWeiS, et al.In pursuit of degenerative brain disease diagnosis: dementia biomarkers detected by DNA aptamer-attached portable graphene biosensor. Proc Natl Acad Sci U S A2023; 120: e2311565120.
83.
KwonSSKimDYunM, et al.The role of graphene patterning in field-effect transistor sensors to detect the tau protein for Alzheimer’s disease: simplifying the immobilization process and improving the performance of graphene-based immunosensors. Biosens Bioelectron2021; 192: 113519.
84.
DerkusBAcar BozkurtPTuluM, et al.Simultaneous quantification of Myelin Basic Protein and Tau proteins in cerebrospinal fluid and serum of Multiple Sclerosis patients using nanoimmunosensor. Biosens Bioelectron2017; 89: 781–788.
85.
SinhaSSJonesSPramanikA, et al.Nanoarchitecture based SERS for biomolecular fingerprinting and label-free disease markers diagnosis. Acc Chem Res2016; 49: 2725–2735.
86.
YeMJiangMChengJ, et al.Single-layer exfoliated reduced graphene oxide-antibody Tau sensor for detection in human serum. Sens Actuators B Chem2020; 308: 127692.
87.
JaliliRChenaghlouSKhataeeA, et al.An electrochemiluminescence biosensor for the detection of Alzheimer’s tau protein based on gold nanostar decorated carbon nitride nanosheets. Molecules2022; 27: 431.
88.
ZhuRMakwanaKMZhangY, et al.Blocking tau transmission by biomimetic graphene nanoparticles. J Mater Chem B2023; 11: 7378–7388.
89.
Walton-RaabyMWoodsRKalyaanamoorthyS. Investigating the theranostic potential of graphene quantum dots in Alzheimer’s disease. Int J Mol Sci2023; 24: 9476.
90.
WangLLiuXFuJ, et al.Release of methylene blue from graphene oxide-coated electrospun nanofibrous scaffolds to modulate functions of neural progenitor cells. Acta Biomater2019; 88: 346–356.
91.
YangZZhangYYangY, et al.Pharmacological and toxicological target organelles and safe use of single-walled carbon nanotubes as drug carriers in treating Alzheimer disease. Nanomedicine2010; 6: 427–441.
92.
ZeinabadHAZarrabianASabouryAA, et al.Interaction of single and multi wall carbon nanotubes with the biological systems: tau protein and PC12 cells as targets. Sci Rep2016; 6: 26508.
93.
PollackSJDakkakDGuoT, et al.Truncated tau interferes with the autophagy and endolysosomal pathway and results in lipid accumulation. Cell Mol Life Sci2024; 81: 304.
94.
PiovesanaEMagrinCCiccaldoM, et al.Tau accumulation in degradative organelles is associated to lysosomal stress. Sci Rep2023; 13: 18024.
95.
ZhangWXuCSunJ, et al.Impairment of the autophagy–lysosomal pathway in Alzheimer’s diseases: pathogenic mechanisms and therapeutic potential. Acta Pharm Sin B2022; 12: 1019–1040.
96.
SamimiNAsadaAAndoK. Tau abnormalities and autophagic defects in neurodegenerative disorders; a feed-forward cycle. Galen Med J2020; 9: 1681.
97.
XueXWangLRSatoY, et al.Single-walled carbon nanotubes alleviate autophagic/lysosomal defects in primary glia from a mouse model of Alzheimer’s disease. Nano Lett2014; 14: 5110–5117.
98.
LisiSScaranoSFedeliS, et al.Toward sensitive immuno-based detection of tau protein by surface plasmon resonance coupled to carbon nanostructures as signal amplifiers. Biosens Bioelectron2017; 93: 289–292.
99.
Eduarda SchneiderMGuilladeLCorrea-DuarteMA, et al.Development of a biosensor for phosphorylated Tau 181 protein detection in Early-Stage Alzheimer’s disease. Bioelectrochemistry2022; 145: 108057.
100.
YinMXuDYuJ, et al.Impedance spectroscopy for identifying tau protein to monitor anesthesia-based issues. Biotechnol Appl Biochem2022; 69: 1805–1811.
101.
KimKKimMJKimDW, et al.Clinically accurate diagnosis of Alzheimer’s disease via multiplexed sensing of core biomarkers in human plasma. Nat Commun2020; 11: 119.
102.
PinalsRLYangDRosenbergDJ, et al.Quantitative protein corona composition and dynamics on carbon nanotubes in biological environments. Angew Chem Int Ed2020; 59: 23668–23677.
103.
TeixeiraMILopesCMAmaralMH, et al.Navigating neurotoxicity and safety assessment of nanocarriers for brain delivery: strategies and insights. Acta Biomater2024; 189: 25–56.
104.
GangulySSarkarPSarkarD, et al.Carbon nanoarchitectures: toxicity barrier and therapeutic advancement. Chem Res Toxicol2025; 38: 1613–1637.
105.
MaXTianYYangR, et al.Nanotechnology in healthcare, and its safety and environmental risks. J Nanobiotechnol2024; 22: 715.
106.
Chung D eunCRoemerSPetrucelliL, et al.Cellular and pathological heterogeneity of primary tauopathies. Mol Neurodegeneration2021; 16: 57.
107.
BuchholzSZempelH. The six brain-specific tau isoforms and their role in Alzheimer’s disease and related neurodegenerative dementia syndromes. Alzheimers Dement2024; 20: 3606–3628.
